Novan, Inc. (NOVN)
| Market Cap | 141.51M |
| Revenue (ttm) | 5.23M |
| Net Income (ttm) | -19.58M |
| Shares Out | 133.69M |
| EPS (ttm) | -0.42 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $1.27 |
| Previous Close | $1.00 |
| Change ($) | 0.27 |
| Change (%) | 27.00% |
| Day's Open | 1.14 |
| Day's Range | 1.09 - 1.45 |
| Day's Volume | 107,466,430 |
| 52-Week Range | 0.22 - 1.45 |
NEW YORK, Jan. 13, 2021 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiducia...
MORRISVILLE, N.C., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that Paula Brown Stafford, President and Chief Executive Officer of ...
– Catalent has a proven track record of accelerating molecules from early development through commercial manufacturing –
– Completion of patient enrollment targeted for Q1 2021 with readout of topline results targeted for Q2 2021 –
NEW YORK, Dec. 14, 2020 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiducia...
– T rading on Nasdaq Capital Market is expected to begin on November 5, 2020 –
– Lead product candidate, SB206 currently being evaluated in B-SIMPLE4 pivotal Phase 3 study in molluscum contagiosum with topline data targeted for Q2 2021 –
- Live moderated video webcast discussion between members of management and Key Opinion Leader, John Browning, MD, FAAD, FAAP, MBA on Tuesday October 27th at 12:00 PM ET - Live moderated video...
- F irst demonstration of antiviral effect of nitric oxide -based medicine against SARS-CoV-2 in an in vitro model that mimics the human airway epithelium
- John M. Gay , V ice P resident , Finance and Corporate Controller with over 20 years of financial and accounting experience appointed as Chief Financial Officer
- Lead product candidate, SB206 currently being evaluated in B-SIMPLE4 pivotal Phase 3 study in molluscum contagiosum with topline data targeted for Q2 2021 -
- Live video webcast with President and CEO, Paula Brown Stafford, on Monday, September 14th at 4:00 PM EDT -
- Topline results targeted for Q2 2021, less than a year away -
- Clinical sites actively enrolling patients -
MORRISVILLE, N.C., July 28, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq: NOVN), today announced an expanded role of Paula Brown Stafford, President and Chief E...
MORRISVILLE, N.C., July 23, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq: NOVN), today announced that it will host a live audio webcast of the Company’s 2020 Annua...
MORRISVILLE, N.C., June 25, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq:NOVN) today announced that the Company anticipates that its current cash position will be ...
MORRISVILLE, N.C., June 24, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq:NOVN) today announced that Paula Brown Stafford, the Company’s President and Chief Executi...
MORRISVILLE, N.C., April 30, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq:NOVN) today announced that the Company has received meeting minutes from the April 1, 202...
MORRISVILLE, N.C., April 20, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq:NOVN) today announced that it has engaged H.C. Wainwright & Co., LLC (“H.C. Wainwright & ...
Top Ranked Momentum Stocks to Buy for April 6th
MORRISVILLE, N.C., April 03, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq:NOVN) today announced that the Company has conducted its Type C meeting with the U.S. Foo...
Top Ranked Momentum Stocks to Buy for April 2nd
Top Ranked Momentum Stocks to Buy for March 30th
MORRISVILLE, N.C., March 26, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced the closing of the Company’s previously announced registered direct...
MORRISVILLE, N.C., March 24, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that it has entered into definitive agreements with several institu...
MORRISVILLE, N.C., March 23, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq:NOVN) today announced data from the prospectively planned safety evaluation through Week ...
Inside the top-ranked stocks that have been exhibiting rising P/E ratios.
Top Ranked Momentum Stocks to Buy for March 11th
MORRISVILLE, N.C., March 03, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company" or "Novan") (NASDAQ:NOVN) today announced the closing of the Company’s previously announced underwritten publ...
MORRISVILLE, N.C., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced the pricing of the Company's previously announced underwritten publi...
MORRISVILLE, N.C., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ: NOVN) today announced that it intends to offer and sell a combination of shares of its co...
MORRISVILLE, N.C., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq:NOVN) today announced that the Company has received approximately $1.0 million funding fro...
MORRISVILLE, N.C., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq:NOVN) today provided an update on several aspects of its Phase 3 B-SIMPLE program (B-SIMPL...
Shares of Novan Inc. novn fell 72% in premarket trading on Friday after the biotechnology company said Thursday that its experimental treatment for molluscum contagiosum, a type of skin infect...
MORRISVILLE, N.C., Dec. 18, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq:NOVN) today announced that Paula Brown Stafford, currently President and Chief Operating O...
Novan (NOVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MORRISVILLE, N.C., Oct. 18, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq:NOVN) today announced that the Company has submitted a request for a pre-IND meeting with ...
MORRISVILLE, N.C., Oct. 08, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq:NOVN) today announced that the Company’s Phase 2 molluscum study, designed to evaluate top...
MORRISVILLE, N.C., Sept. 20, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq:NOVN) today announced that the Company has received a grant from the U.S. Department of D...
MORRISVILLE, N.C., Sept. 11, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq:NOVN) today announced that the Compensation Committee of Novan’s Board of Directors grant...
MORRISVILLE, N.C., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq:NOVN) today announced that the Company has entered into a Common Stock Purchase Agreement...
MORRISVILLE, N.C., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq:NOVN) today announced the appointment of Michelle Patterson as Vice President of Project ...
About NOVN
Novan, Inc., a clinical development-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage dermatology product candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal na... [Read more...]
| Industry Biotechnology | IPO Date Sep 21, 2016 |
| CEO Paula Stafford | Employees 24 |
| Stock Exchange NASDAQ | Ticker Symbol NOVN |
Financial Performance
In 2019, Novan's revenue was $4.90 million, a decrease of -18.28% compared to the previous year's $5.99 million. Losses were -$30.38 million, 3.89% more than in 2018.
Analyst Forecasts
According to one analyst, the rating for Novan stock is "Buy" and the 12-month stock price forecast is 2.75.